Aims-To understand the role of ancestral genomic background in substance dependence (SD) genome-wide association studies (GWAS), we analyzed population diversity at genetic loci associated with SD traits and evaluated its effect on GWAS outcomes.
proteins that interact with the protein products of other SD-associated genes via proteinprotein interactions.
To gain insight into the genetic mechanisms at the basis of ancestry differences in the significant outcomes of GWAS of traits related to alcohol (AD), nicotine (ND) and opioid dependencies (OD), we analyzed the relationship of ancestral genomic background to GWAS results. Specifically, we investigated common and rare variation in genes with alleles significantly associated with SD traits based on GWAS and the genes that interact with them in four ancestry groups: African, admixed American (defined in the Materials and methods), Asian and European. Then, to verify the effect of this genetic variation on GWAS findings, we analyzed our GWAS discovery samples (Yale-Penn) on AD [4] and SAGE (Study of Addiction: Genetics and Environment) samples available in dbGAP (accession number phs000092.v1.p) [24] . Specifically, we tested whether variants with high allele ΔFs show significant effects on the associations between GWAS-relevant alleles (i.e., genetic variants identified by GWAS) and AD, explaining the differences observed between African-Americans (AA) and European-Americans (EA) -by evaluating whether the inclusion of ancestry-differentiated variants as covariates significantly modifies the associations observed. To exclude the possibility that the nonreplication of GWAS between AAs and EAs in AD GWAS is due to power differences attributable to allele ΔFs for GWAS-relevant alleles, we considered GWAS-relevant alleles that do not have large ΔFs between African and European ancestry subjects, and that showed genome-wide significance in one ancestry (p < 5*10 −8 ) and no significance in the other population (p > 0.05).
Materials & methods

Identification of relevant genes via GWAS
To find alleles potentially associated with SD traits, we searched Medline in November 2013 using combinations of the following keywords: 'drugs', 'alcohol', 'nicotine', 'opioid', 'addiction', 'dependence', 'genome-wide association studies' and 'GWAS'. We identified 16 articles, in which at least a gene showed near-significant association with a trait related to at least one of the considered drug dependencies (p < 5*10 −7 ). A total of 24 genes (hereafter indicated as GWAS-relevant genes) were identified, as shown in Supplementary Table 1 . We observed that the GWAS results are more consistent within the ancestral groups than between them, as anticipated. This trend is clearer for SD traits that were investigated by independent GWAS.
Identification of interacting genes/proteins
We used several interaction/pathway tools to identify genes and proteins interacting with the identified GWAS-relevant genes: STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) [25] , MINT (Molecular INTeraction Database) [26] , KEGG (Kyoto Encyclopedia of Genes and Genomes) [27] and Pharm-GKB (The Pharmacogenomics Knowledgebase) [28] . For STRING analysis, we excluded text-mining from the active prediction methods and considered outcomes with the highest confidence (STRING score >0.900). For the MINT analysis, we considered Homo sapiens, as the reference organism, and interactions with a score greater than 0.50. For KEGG and PharmGKB, we considered interacting genes/proteins those involved in direct interactions: either involvement in the same catalytic reactions or immediately preceding/subsequent catalytic reactions with proteins encoded by GWAS-relevant genes. With these criteria, we identified 82 interacting proteins. Supplementary Figures 1, 2 
Functional annotation analysis
We used three different tools for functional annotation analysis. To distinguish between variants with functional effects (i.e., variants that affect gene regulation and/or protein activity) and variants with no regulatory or activity effects, we used VARIANT (VARIant ANalysis Tool) [30] . Based on the information obtained from VARIANT, we distinguished: variants likely to be nonfunctional (i.e., variants mapping to putative nonfunctional regions), variants with low potential for functional effect (i.e., variants with only a generic annotation: 'located in a regulatory region annotated by Ensembl') and variants with high potential for functional effect (i.e., variants with a specific annotation: 'CpG island', 'miRNA target site', 'splice site', 'splice donor variant', 'RNA polymerase promoter', 'transcription factor binding site', 'splice acceptor variant', 'non-synonymous variant' or 'stop codon'). In the annotation analysis performed by VARIANT based on in silico evidence, we considered only information related to transcripts annotated in the Consensus Coding Sequence (CCDS) database. We also used rSNPBase (database for curated regulatory SNPs) and RegulomeDB [31, 32] to further investigate variants potentially associated with epistatic effects on SD risk alleles. Both rSNPBase and RegulomeDB perform functional annotation on the basis of in silico and experimental evidences.
Identification of ancestry-related differences in common & rare variants
To identify the ancestry-related differences in GWAS-relevant genes and their interacting partners, we performed distinct analyses for variants with minor allele frequency (MAF) ≥1% (common variants) and variants with a MAF <1% (rare variants; RVs).
To identify the allele ΔF for common variants in the ancestry groups, we used the method proposed by Hofer and colleagues [14] . We chose this metric based on allele ΔF rather than others commonly used in population genetics (e.g., Wright's fixation index) in order to make our analysis clear also to nonexperts in the field. For each allele i, we computed the average allele frequency p ij within each ancestry group j, as well as the difference with the average frequency computed over all other populations as ΔF = |p ij − p −ij |, where p −ij is the average frequency of allele i in all populations not belonging to the ancestry group j. A permutation test (n = 10,000) was performed to determine whether the MAF between the populations within ancestry groups and the rest of the populations was significantly different than expected by the chance.
For RVs, we analyzed the occurrences of functional RVs among all of the ancestry groups and used an equation to estimate ancestry differences in the occurrence of functional RVs. Using VARIANT annotation analysis, we distinguished functional variants from nonfunctional variants. Based on this information, for each gene we estimated the occurrence of functional RVs as the ratio of functional RVs to all observed variants. Specifically, for each gene i, we computed the average ratio r ij within each ancestry group j, as well as the difference with the average ratio computed over all other populations as rΔF = |r ij − r −ij |, where r −ij is the average ratio of gene i in all populations not belonging to the ancestry group j. A permutation test (n = 10,000) was performed to evaluate the significance of differences between the populations within an ancestry group compared with the rest of the populations.
Analysis in GWAS data of the effect of common variants with ΔF>0.10
To verify the effect of common variants with high ΔF on genome-wide significant associations, we analyzed two independent datasets used in a recent published AD GWAS [4] . Specifically, the datasets used in the present analysis comprise our Yale-Penn samples and SAGE samples, the latter obtained via dbGAP application. The Yale-Penn dataset includes 3318 AAs and 2379 EAs. The SAGE dataset includes 1195 AAs and 2528 EAs. Information about the genotyping, quality control and imputation analysis was published previously [4] . Considering the outcomes obtained by our previous AD GWAS, ten variants were found to be genome-wide significant (p < 5*10 −8 ) for AD symptom count in an ancestry group with nonsignificant results for the other one (Supplementary Table 2 ). Due to the strong linkage disequilibrium (LD) among some significant associations in this AD GWAS, we selected three independent variants from the total of ten: PDLIM5 rs10031423, ADH1B rs1693457 and ADH1C rs6846835. Specifically, PDLIM5 rs10031423 showed R 2 = 0 with respect to ADH1B rs1693457 and ADH1C rs6846835 in AAs and EAs, whereas ADH1B rs1693457 and ADH1C rs6846835 showed R 2 = 0 in EAs and R 2 = 0.15 in AAs. Slight differences exist for these variants in the present association results compared with the published AD GWAS (Supplementary Table 3) , because in the present study we used the original SAGE-imputed data, and symptom counts instead of substance dependence diagnosis to adjust for multiple dependencies. To estimate the effect of common variants on the genome-wide significant associations with Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) symptom counts for AD, among the common variants investigated in the first part of the study, we selected those with ΔF>0.10 in African or European ancestries that are present in Yale-Penn and SAGE datasets (12,969 variants for African ancestry, and 8721 variants for European ancestry). We chose this threshold in order to exclude those variants with minimal allele ΔF among human populations. Then, performing separate analyses for AAs and EAs and for the Yale-Penn and SAGE datasets, we estimated the association of rs10031423, rs1693457 and rs6846835 with AD symptom counts in accordance with two different models using the R package genome-wide association/interaction analysis and rare variant analysis with family data (GWAF) to fit a generalized estimating equations model to correct for correlations among related individuals [33] . The first model ('A') tested the association of the imputed minor allele dosage with the DSM-IV symptom counts for AD considered as phenotype and using DSM-IV cocaine dependence symptom counts, DSM-IV OD symptom counts, DSM-IV ND symptom counts, sex, age and the first three ancestry principal components, as covariates. The second model ('B') performed the same analysis with the addition of a further covariate, a variant with ΔF>0.10. Then, we meta-analyzed the results obtained in the Yale-Penn and SAGE datasets for each ancestry group, applying the following equations:
where β META , β Yale-Penn and β SAGE are the β values in the meta-analysis, Yale-Penn and SAGE datasets, respectively. The meta-analyzed p-values were calculated using METAL software [34] . To estimate the effect of each tested variant with ΔF >0.10, we calculated the z-score according to the following equation:
where META1 defined the meta-analyzed β values obtained from model B and META0 for the meta-analyzed parameter of model A. In accordance with Bonferroni correction for multiple testing, Z scores >|4.388| and |4.473| were considered significant in EAs and AAs, respectively.
Results
Considering the results of our gene-gene/protein-protein interaction's investigation, we constructed three interaction networks, one each for AD, ND and OD. Supplementary Figure  1 shows the AD interaction network. We observed only ADH1B and ADH1C interacting between themselves and with other common interacting partners. The other AD GWASrelevant genes were related only to specific interacting partners (i.e., CTBP2, HTR1A, GSS, KCNB2) or were not related to any interacting partners (i.e., THSD7B, SERINC2, NALCN, PKNOX2, DSCAML1, METAP1, KIAA0040, C15orf53, PDLIM5). In the ND interaction network, we observed that CHRNA3 and CHRNA5 have common interacting proteins.
Conversely, CHRNB3 and ARHGAP10 did not interact (Supplementary Figure 2) . In the OD interaction network, NCK2 and KCNG2 showed many interacting partners, having common interactions with PARVA and KCNC1, respectively (Supplementary Figure 3) . In the OD interaction analysis, we saw no interactions for the APBB2 gene.
The ΔF analysis of common variants (n = 51,079) indicated that allelic differences are greater in subjects of African ancestry (99.9th percentile of African ΔF = 0.690) than in those of Asian (99.9th percentile of Asian ΔF = 0.627), European (99.9th percentile of European ΔF = 0.422) or admixed-American ancestries (99.9th percentile of admixedAmerican ΔF = 0.281) (Figure 1 ). Considering each SD diagnosis separately, we observed high ΔF values in variants potentially associated with a large functional effect in GWASrelevant genes and their interacting partners in AD, ND and OD (Supplementary Tables 4, 5 & 6, respectively). Table 1 reports the common variants with top ΔF that are also potentially associated with regulatory functions observed in each GWAS-relevant gene.
In the analysis of RVs, we observed that the distribution of r values differed significantly between those of African ancestry and those of Asian (p Bonferroni <0.05), European (p Bonferroni <0.001) and admixed-American ancestries (p Bonferroni <0.001) (Figure 2 ).
Considering the rΔF values for each analyzed gene, we observed only two significant outcomes for African ancestry: ZEB1 (Africa rΔF = 0.186; p = 0.005), and HDAC1 (Africa rΔF = 0.316; p = 0.004). These are interactive partners; we did not observe any significant difference for genome-wide significant genes. Supplementary Table 6 shows the top 1% of rΔF values for each ancestry group. Although no ancestry-related differences were observed for the occurrence of RVs in GWAS-relevant genes, high r values in GWAS-relevant genes can be seen in the overall 1KG population (r overall = 0.529 ± 0.215; Table 2 ).
As mentioned above, we hypothesized that allele ΔFs in variants with functional impact may explain the ancestry-related differences observed in drug dependence GWAS. To verify this hypothesis, we analyzed two different datasets with AA and EA samples used in our recently published AD GWAS, as described above. In this study, ten GWAS-significant variants were observed associated with AD symptom counts in one ancestry group but not in the other (Supplementary Table 2 & 3) -i.e., in either AAs or EAs but not both. These genetic variants are located in ADH1B, ADH1C and PDLIM5. In PDLIM5, we observed large ΔF values for African ancestry, but the PDLIM5 significant variant (i.e., rs10031423) showed low ΔF values in all ancestry groups (Supplementary Figure 4) . In ADH1B, we observed large ΔF values for Asian ancestry (i.e., ΔF>0.6), but low ΔF values of ADH1B variants for European and African ancestries (Supplementary Figure 5) . In ADH1C, extreme ΔF values were observed for Asian ancestry (i.e., ΔF>0.6), and most of the Asian ΔF peaks are genome-wide significant variants for AD symptom counts (Supplementary Figure 6) . Both ADH1B and ADH1C ΔF top values are included in the top 0.1% of the distribution of Asian ΔFs. To check whether the high ΔF values of ADH1B and ADH1C in Asians and PDLIM5 in Africans are due to human demographic history or to natural selection processes, we verified the integrated Haplotype Score of these loci using the Haplotter application [35] . Significant signatures of natural selection are confirmed in Asians for Figure 7) , while a nonsignificant outcome was observed for PDLIM5.
As noted above, due to the high LD present among the ten genome-wide significant variants considered here, we chose three independent variants (i.e., PDLIM5 rs10031423, ADH1B rs1693457 and ADH1C rs6846835).
In EAs PDLIM5 rs10031423 showed a significant association with AD symptom counts. In EAs, we identified 59 variants with significant effect on this association. Except for ADH1B rs1229984 (i.e., a genome-wide significant variant for AD symptom counts in EAs), they are all located in the PDLIM5 gene region, and 36 of them have an r 2 <0.2 with rs10031423 both in the Yale-Penn and SAGE datasets (Supplementary Table 7 ). Among these non LD variants, there are ADH1B rs1229984 and PDLIM5 rs2452594. This latter may have functional impact on the PDLIM5 function (RegulomeDB score = 2b, i.e., TF binding + any motif + DNase Footprint + DNase peak) and this variant reduces the association of rs10031423 with AD symptom count (meta-analyzed p-value from 7.3510 −6 to 5.75*10 −4 ). In AAs, we identified 88 variants with significant z-scores (Supplementary Table 8 ). Except for KCND2 rs12333476, they are all located on chromosome 4, as rs10031423. Among these variants, rs6853490 (z = −20.085) showed that a high African ΔF, may play a role in PDLIM5 regulation (RegulomeDB score = 2b, i.e., TF binding + any motif + DNase Footprint + DNase peak), and increase the association of rs10031423 with AD symptom count in AAs (meta-analyzed p-value from 0.276 to 0.097). Regarding ADH1B rs1693457 (significant in AAs), through our analysis of AAs, we identified 27 variants with significant z-scores. They are all located in the surrounding regions of rs1693457 (Supplementary Table  9 ). Among these, 18 variants showed r 2 <0.2 with rs10031423 both in the Yale-Penn and SAGE datasets. In accordance with RegulomeDB, none of these seem to have functional impact on PDLIM5 gene function. However, rs12639887 (z = 16.997) showed the highest African ΔF among these (Africa ΔF = 0.39). Both the VARIANT tool and rSNPbase identified it as regulatory SNP, and rs12639887 reduces the association significance of rs1693457 with AD symptom counts (meta-analyzed p-value from 3.40*10 −9 to 1.10*10 −5 ). In EAs, we identified 106 variants with significant z-scores. All of these are located in the regions surrounding rs10031423 (Supplementary Table 10 ). According to RegulomeDB, none of them showed notable evidence of functional regulatory effects, and the strongest increase of significance was observed for rs1229984 (z = 13.369; meta-analyzed p-value from 0.726 to 0.189). In AAs, the analysis of ADH1C rs6846835 (significant in AAs) revealed 15 variants with significant z-scores. All of these are located on chromosome 4, as rs6846835 (Supplementary Table 11 ). Among them, only ten variants present an r 2 with rs6846835<0.2. Considering the non LD variants, rs12639887 showed significant effects on both ADH1B rs1693457 and ADH1C rs6846835. In the analysis of ADH1C rs6846835, rs12639887 showed a strong effect on the association with AD symptom count (z = −6.015; meta-analyzed p-value from 5.65*10 −9 to 0.237). Stratifying the AA and EA samples for rs12639887 genotype, we observed the same trend in both ancestry groups for the association between ADH1C rs6846835 and AD symptom count (Supplementary Table 12 ). Regarding the analysis of ADH1C rs6846835 in EAs, we observed 72 variants with significant z-scores. They are all located on chromosome 4 (Supplementary Table 13 ).
Among these variants, only rs4147541 showed evidence of regulatory function (RegulomeDB score = 3a, i.e., TF binding + any motif + DNase peak) and an effect that increased the association significance of ADH1C rs6846835 with AD symptom counts in EAs (z = 39.468; meta-analyzed p-value from 0.950 to 0.041).
Considering the PDLIM5, ADH1B and ADH1C analyses, we observed that the most significant findings are related to common functional alleles with high African or European ΔFs located in the regions surrounding genome-wide significant variants. To analyze the local haplotype structure of the PDLIM5-ADH1B-ADH1C region (chr4:95,379,741-100,274,157), we used 1KG Phase 1 data from the ASW populations to investigate AAs and from the CEU to investigate EAs, considering those ancestry variants with relevant effects on PDLIM5 rs10031423, ADH1B rs1693457 and ADH1C rs6846835 associations with AD outcomes. In accordance with the method of Gabriel and colleagues [36] , we observed 14 and 11 haplotype blocks in ASW and CEU, respectively (Supplementary Figures 8 & 9) . In ASW, PDLIM5 included ten haplotype blocks. The ancestry variants with effects on PDLIM5 genome-wide significant association are located in the haplotype blocks closer to rs10031423. Regarding the ADH1B rs1693457 genome-wide significant association, the variants with relevant effects are mainly located within METAP1 and ADH1B haplotypes. For the ADH1C rs6846835 genome-wide significant association, most variants with relevant effects are located in METAP1 and ADH1C haplotypes, and they showed relevant effects also on ADH1B association. In CEU, the PDLIM5 gene region includes eight haplotype blocks, and the genome-wide significant variant is located in last (i.e., 3′-most) haplotype block (i.e., Block 8). Most variants with significant effects on the genome-wide association are located in Block 1 and Block 2; single haplotypes are present for each of the remaining genes (i.e., METAP1, ADH1B and ADH1C). The variants with relevant effects on the ADH1B rs1693457 genome-wide significant association are mainly located in METAP1 and ADH1B haplotypes, while the relevant findings related to ADH1C rs6846835 genome-wide association are located in an ADH1C haplotype and most of them showed significant effects also on the ADH1B rs1693457 genome-wide association.
Discussion
GWAS for drug dependence traits have identified several significant risk alleles, but replication studies in different ancestry groups often fail to reproduce these outcomes [12, 13] . In the present study, we tested the effect of genetic background (variants located in the surrounding regions or in functional partners) on the significantly-associated variants. Our results provided significant evidence that local ancestry differences can partially explain the ancestry difference observed in GWAS. Specifically, we observed that when adjusting for these local ancestry-related variants, the differences between African-Americans and European-Americans tend to diminish.
Our investigation of gene-gene/protein-protein interactions highlighted multiple interactions of GWAS-relevant genes with other genome-wide relevant loci or other genes involved in the same molecular pathways. Genetic variations among these interacting partners may have an effect on the predisposition to drug dependence. However, we also found that certain genome-wide relevant genes were not integrated into the network. This suggests that there is missing information in the experimental evidence pertaining to genegene/protein-protein interaction in the predisposition to drug dependence -a result that is hardly surprising. Other approaches have been used to integrate drug dependence GWAS data with the human protein interactome [37] . Comparing these approaches, we observed some common features and some differences, which are likely attributable to the fact that the present network analysis is based only on experimental evidence independent from genetic data. Therefore, by analyzing our interaction networks, we have confidently investigated human variation in genes that directly interact with the identified GWASrelevant genes.
Our analysis of the ancestry-related allele ΔF of common variants indicated that African ancestry is the most divergent group, in agreement with the current knowledge about genetics of human demographic history [38, 39] . Conversely, the admixed-American group showed lower allele ΔFs than the other ancestry groups. It is highly likely that this is due to the complex admixture of African, Amerindian and European ancestries present in these populations [29] . When considering the observed ancestry-related differences in common variants in both GWAS-relevant genes and their interactive partners, we detected a number of variants with noteworthy allele ΔFs which are also potentially involved in regulatory mechanisms, suggesting their role in the diverse outcomes observed in drug dependence GWAS-among human populations. Regarding the rare variants analysis, we observed that there are differences among ancestry groups for the occurrence of regulatory rare variants. These differences are significant when we considered the entire genome, but, when we focused on specific gene regions, they are not statistically significant. The result observed, considering genomic differences, is in accordance with recent evidence that has indicated differences in the stratification of functional RVs among human populations [40, 41] . As is the case for common variants, the differences in RVs between African and non-African populations may be attributed to human demographic history. However, the specific-gene analysis suggests that, in drug dependence GWAS, confounding effect due to rare variation is not linked to the ancestry of the investigated populations. Nevertheless, we cannot exclude that RVs could have a population-specific effect on an SD-phenotype, since their effect could depend on a permissive epistatic genetic background present in one population group but not another. Moreover, the high rates of functional RVs in both GWAS-relevant genes and their interactive partners also indicate that rare variation may strongly confound outcomes of drug dependence GWAS, as postulated for other complex phenotypes related to drug response [42, 43] .
The ΔF analysis of genes with AD GWAS ancestry-specific significant alleles showed the strong diversity of ADH1B and ADH1C variation between Asian and non-Asian populations. Previous studies indicated that ADH1B-ADH1C genetic diversity between Asians and nonAsians is due in part to a selective pressure [44] [45] [46] , suggesting a potential effect on ADHassociated traits, such as AD. A recent GWAS on AD traits in a Chinese study population indicated that ADH1B and ADH1C did not contain alleles significantly associated with AD traits, but ALDH2, another alcohol metabolism-related gene and an interactive partner of both ADH1B and ADH1C, showed AD risk alleles consistent with many prior observations [47] . This difference between non-Asian ancestries (i.e., AAs and EAs: genome-wide significance of ADH genes for AD traits) and Asian one (non-genome-wide significance of ADH genes for AD traits) may ultimately be attributable to the effect of natural selection on genetic variation of ADH-gene cluster.
Our analysis on AD GWAS datasets indicated that multiple variants, located in the surrounding regions of genome-wide significant alleles, have effects modifying the associations between significant alleles and AD symptom counts. Most of them showed high allele ΔFs in African or European ancestries and are potentially involved in regulatory mechanisms. Among them, in AAs, rs12639887 showed significant effects both on ADH1B rs1693457 and ADH1C rs6846835 association with AD symptom counts. This variant is located in a PDLIM5 intronic region, approximately 5 Mb downstream with respect to ADH1B and ADH1C. Both VARIANT and rSNPbase defined it as a regulatory SNP. In particular, VARIANT describes it as being located in an H3K36me3 region, whereas rSNPbase designates it as being involved in proximal, distal and RNA binding proteinmediated regulations. Unfortunately, to best of our knowledge, no information is currently available regarding the role of rs12639887 in ADH1B and ADH1C expression or methylation status in brain tissues. However, according to annotation analysis, we can hypothesize that rs12639887 plays a role in determining the differences observed between AAs and EAs in AD GWAS outcomes of ADH1B and ADH1C. In addition to this single case, our data generally revealed that ancestry-related variability in AD GWAS-relevant genes and their surrounding regions can explain some differences in the outcomes of drug dependence GWAS among human populations. Consequently, the differences among ancestry groups in terms of AD genetic predisposition seem not to be influenced by general variation across the genome -that is, these differences may reside in a collection of identifiable ancestry-specific risk alleles. Accordingly, the analysis of local haplotype structure of the PDLIM5-ADH1B-ADH1C region confirmed how population differences in haplotype structure can affect GWAS findings.
Conclusion
Our data furnish novel information not only about the relationship between AD and ancestry, but also about the interactions between GWAS-relevant alleles and cis-regulatory variants. Further analyses based on an evolutionary approach may provide other relevant knowledge about the predisposition of AD.
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Executive summary
Background
• Genome-wide association studies (GWAS) of substance dependence traits have identified numerous significant risk alleles, but replication studies on different ancestry groups have often failed to reproduce these outcomes.
Aim
• To understand the role of ancestral genomic background in substance dependence (SD) GWAS, we analyzed population diversity at genetic loci associated with SD traits and evaluated its effect on the significant outcomes of GWAS in different ancestry groups.
Results
• We observed high ancestry-related frequency differences in common functional alleles in GWAS-relevant genes and their interactive partners.
• We also identified significant ancestry differences in the genome-wide occurrence of regulatory rare variants between African and non-African population, but gene-specific analysis confirmed few significant ancestry differences.
• The analysis of SD GWAS datasets indicated that common functional alleles with high African or European frequency differences have significant effects on the outcomes of genome-wide significant loci observed in African-and European-Americans.
Conclusion
• We observed that population differences in SD GWAS outcomes seem not to be influenced by general variation across the genome, but rather are due to ancestry-related local haplotype structures at SD-associated loci. Table 1 Top frequency difference value of common variants potentially associated with functional effects for each gene. 
